Delcath Systems (NASDAQ:DCTH) Stock Rating Lowered by Wall Street Zen

Delcath Systems (NASDAQ:DCTH) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Evercore set a $27.00 price objective on Delcath Systems in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Delcath Systems in a research note on Friday, January 9th. Stephens cut their price target on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research decreased their price objective on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Price Performance

DCTH opened at $8.90 on Friday. The firm has a 50 day simple moving average of $9.98 and a 200 day simple moving average of $10.19. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $18.23. The company has a market cap of $309.28 million, a price-to-earnings ratio of 127.14 and a beta of 0.38.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.70%. As a group, analysts expect that Delcath Systems will post -0.79 EPS for the current year.

Delcath Systems announced that its board has initiated a share repurchase program on Thursday, November 20th that allows the company to buyback $25.00 million in shares. This buyback authorization allows the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems in the second quarter valued at approximately $26,000. Russell Investments Group Ltd. bought a new position in Delcath Systems in the third quarter valued at $29,000. Tower Research Capital LLC TRC acquired a new stake in Delcath Systems in the 2nd quarter valued at $40,000. Ameritas Investment Partners Inc. bought a new stake in Delcath Systems during the 2nd quarter worth about $42,000. Finally, Legal & General Group Plc bought a new stake in Delcath Systems during the 2nd quarter worth about $46,000. Institutional investors own 61.12% of the company’s stock.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Company reported Q4 and full‑year 2025 results with Q4 revenue of $20.7M and full‑year revenue of $85.2M; EPS of ($0.05) beat consensus by $0.01 — evidence of improving commercial execution. BusinessWire Release
• Positive Sentiment: Management is targeting at least $100M in revenue for 2026 and plans to expand to ~40 treatment centers, signaling a clear growth roadmap and potential material revenue upside if execution continues. Seeking Alpha
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to ~$100.0M (effectively in line with consensus ~100.1M); guidance confirms the growth target but leaves little upside vs. street estimates absent faster center rollout or higher per‑center revenue. MarketBeat Earnings
• Neutral Sentiment: BTIG cut its price target from $23 to $19 but kept a “buy” rating—still implying substantial upside from current levels, though the downgrade signals more conservative near‑term expectations from at least one sell‑side shop. Street Insider

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.